How Much HIV is Alive? The Challenge of Measuring Replication Competent HIV for HIV Cure Research

Por Ananworanich, Jintanat, Mellors, John W.
Publicado no EBioMedicine (2015)

Interruption of antiretroviral therapy to augment immune control of chronic HIV-1 infection: Risk without reward

Por Abbas, Ume L., Mellors, John W.
Publicado em 2002

HIV-1 Drug Resistance Resulting from Antiretroviral Therapy Far Exceeds That From Pre-exposure Prophylaxis

Por Parikh, Urvi M., Mellors, John W.
Publicado em 2012

Changes in HIV reservoirs during long-term antiretroviral therapy

Por Hong, Feiyu F., Mellors, John W.
Publicado no Curr Opin HIV AIDS (2015)

Should We Fear Resistance from Tenofovir/Emtricitabine PrEP?

Por Parikh, Urvi M., Mellors, John W.
Publicado no Curr Opin HIV AIDS (2016)

Pretreatment HIV-1 drug resistance is strongly associated with virologic failure in HIV-infected patients receiving partly active antiretroviral regimens

Por Parikh, Urvi M, Mellors, John W
Publicado no Future Microbiol (2012)

HIV persistence in the CNS: the final frontier for a cure?

Por Lewin, Sharon R, Mellors, John W
Publicado no J Virus Erad (2016)

Longitudinal changes in HIV DNA in HIV controllers: what do they mean?

Por Hsu, Denise C, Mellors, John W
Publicado no J Int AIDS Soc (2019)

Detection of SARS-CoV-2 RNA in Blood of Patients with COVID-19: What Does It Mean?

Por Jacobs, Jana L, Mellors, John W
Publicado no Clin Infect Dis (2020)

Nonhuman Primate Models for HIV Cure Research

Por Apetrei, Cristian, Pandrea, Ivona, Mellors, John W.
Publicado em 2012

Telemedicine and Infectious Diseases Practice: A Leap Forward or a Step Back?

Por Abdel-Massih, Rima C, Mellors, John W
Publicado no Open Forum Infect Dis (2019)

Regulatory T cells: the ultimate HIV reservoir?

Por Rocco, Joseph, Mellors, John W, Macatangay, Bernard JC
Publicado no J Virus Erad (2018)

Potential Impact of Antiretroviral Chemoprophylaxis on HIV-1 Transmission in Resource-Limited Settings

Por Abbas, Ume L., Anderson, Roy M., Mellors, John W.
Publicado em 2007

Simplification Strategies to Reduce Antiretroviral Drug Exposure: Progress and Prospects

Por McKinnon, John E., Mellors, John W., Swindells, Susan
Publicado em 2009

Mechanism by which a Glutamine to Leucine Substitution at Residue 509 in the Ribonuclease H Domain of HIV-1 Reverse Transcriptase Confers Zidovudine Resistance

Por Brehm, Jessica H., Mellors, John W., Sluis-Cremer, Nicolas
Publicado em 2008

The critical roles of treatment interruption studies and biomarker identification in the search for an HIV cure

Por Li, Jonathan Z., Smith, Davey M., Mellors, John W.
Publicado no AIDS (2015)

HIV-1 Virion Production from Single Inducible Proviruses following T-Cell Activation Ex Vivo

Por Bui, John K., Mellors, John W., Cillo, Anthony R.
Publicado no J Virol (2016)

The K65R Mutation in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Exhibits Bidirectional Phenotypic Antagonism with Thymidine Analog Mutations

Por Parikh, Urvi M., Bacheler, Lee, Koontz, Dianna, Mellors, John W.
Publicado em 2006

Adaptation of advanced clinical virology assays from HIV-1 to SARS-CoV-2

Por McCormick, Kevin D., Mellors, John W., Jacobs, Jana L.
Publicado no Curr Opin HIV AIDS (2021)

Factors Influencing the Emergence and Spread of HIV Drug Resistance Arising from Rollout of Antiretroviral Pre-Exposure Prophylaxis (PrEP)

Por Abbas, Ume L., Hood, Gregory, Wetzel, Arthur W., Mellors, John W.
Publicado em 2011